Deutsche Bank AG Has $1.61 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Deutsche Bank AG raised its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 49.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,398 shares of the biopharmaceutical company's stock after purchasing an additional 41,720 shares during the period. Deutsche Bank AG owned 0.10% of Dynavax Technologies worth $1,614,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DVAX. Barclays PLC raised its stake in shares of Dynavax Technologies by 137.4% during the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock worth $3,371,000 after purchasing an additional 175,118 shares in the last quarter. Ballentine Partners LLC bought a new position in shares of Dynavax Technologies in the 4th quarter valued at approximately $137,000. Nisa Investment Advisors LLC raised its stake in shares of Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after acquiring an additional 1,076 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Dynavax Technologies in the 4th quarter valued at approximately $990,000. Finally, Exchange Traded Concepts LLC raised its stake in shares of Dynavax Technologies by 4.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 162,726 shares of the biopharmaceutical company's stock valued at $2,078,000 after acquiring an additional 6,712 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on DVAX shares. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. JMP Securities cut their price objective on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, The Goldman Sachs Group lowered their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Dynavax Technologies presently has an average rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Stock Performance

DVAX traded up $0.35 during midday trading on Thursday, reaching $9.85. The company's stock had a trading volume of 598,054 shares, compared to its average volume of 2,341,218. The stock has a market cap of $1.18 billion, a P/E ratio of 54.68 and a beta of 1.26. The company has a fifty day simple moving average of $11.16 and a 200 day simple moving average of $12.38. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a twelve month low of $9.22 and a twelve month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. Research analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.